Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 191,839,328
  • Shares Outstanding, K 2,317,460
  • Annual Sales, $ 50,135 M
  • Annual Income, $ 7,703 M
  • 36-Month Beta 0.83
  • Price/Sales 3.88
  • Price/Cash Flow 10.91
  • Price/Book 2.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.32
  • Number of Estimates 3
  • High Estimate 1.36
  • Low Estimate 1.29
  • Prior Year 1.29
  • Growth Rate Est. (year over year) +2.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.69 +1.33%
on 10/11/18
87.76 -5.67%
on 10/03/18
-1.65 (-1.95%)
since 09/12/18
3-Month
78.02 +6.10%
on 07/17/18
87.76 -5.67%
on 10/03/18
+3.84 (+4.86%)
since 07/12/18
52-Week
72.30 +14.50%
on 06/28/18
94.19 -12.11%
on 01/26/18
-3.21 (-3.73%)
since 10/12/17

Most Recent Stories

More News
Switzerland : Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden

Novartis announced it will present 33 scientific abstracts at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) being held October 10-12, 2018 in Berlin,...

NVS : 82.78 (+0.71%)
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

CGEN : 3.35 (-4.29%)
JNJ : 133.87 (+0.02%)
LLY : 110.48 (+2.38%)
NVS : 82.78 (+0.71%)
ABBV : 90.69 (-0.01%)
GSK : 38.31 (-0.42%)
BMY : 57.51 (+0.02%)
3 Large-Cap Pharma Stocks Performing Better Than Industry

We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

AZN : 37.15 (-1.30%)
MRK : 69.81 (+2.11%)
LLY : 110.48 (+2.38%)
NVS : 82.78 (+0.71%)
SNY : 42.89 (-1.81%)
AbbVie Settles With Novartis to Delay Humira Biosimilar in US

AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

MYL : 32.11 (-1.50%)
NVS : 82.78 (+0.71%)
ABBV : 90.69 (-0.01%)
AMGN : 197.39 (+1.83%)
Excellent Growth Seen in "Post-Operative Pain Management Market" by 2023 - Competitive Landscape and Revenue Status by Most Prominent Players

VRX.TO : 30.80 (-3.33%)
ENDP : 17.51 (+4.23%)
LLY : 110.48 (+2.38%)
BAX : 71.25 (+1.54%)
NVS : 82.78 (+0.71%)
GSK : 38.31 (-0.42%)
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

Novartis International AG / Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access . Processed and transmitted by West Corporation. The issuer is solely...

NVS : 82.78 (+0.71%)
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.

NVS : 82.78 (+0.71%)
TEVA : 21.38 (+4.55%)
RHHBY : 29.6950 (+0.22%)
BIIB : 330.94 (+1.12%)
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales

Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.

MRK : 69.81 (+2.11%)
LLY : 110.48 (+2.38%)
INCY : 62.56 (+1.31%)
NVS : 82.78 (+0.71%)
VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors

VisionGate, Inc., an integrated, clinical-stage, oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of R. John Glasspool as its Chief Operating and Strategy Officer....

JNJ : 133.87 (+0.02%)
NVS : 82.78 (+0.71%)
Novartis Presents Data on Multiple Sclerosis Drug Gilenya

Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.

NVS : 82.78 (+0.71%)
MNTA : 16.10 (-13.49%)
TEVA : 21.38 (+4.55%)
BIIB : 330.94 (+1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 83.75
1st Resistance Point 83.26
Last Price 82.78
1st Support Level 82.22
2nd Support Level 81.67

See More

52-Week High 94.19
Fibonacci 61.8% 85.83
Fibonacci 50% 83.25
Last Price 82.78
Fibonacci 38.2% 80.66
52-Week Low 72.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar